Global Immuno-oncology Diagnosis Market Strategic Research Report

Scope of the Report

The global Immuno-oncology Diagnosis market size is predicted to grow from US$ 8,807 million in 2025 to US$ 20,613 million in 2032; it is expected to grow at a CAGR of 13.1% from 2026 to 2032.

Immuno-oncology diagnostics refers to a comprehensive system of precise detection and evaluation technologies surrounding tumor immunotherapy. Its core lies in detecting key biomarkers in tumors and their immune microenvironment, combined with molecular diagnostics, immunohistochemistry, and next-generation sequencing to screen patients for suitability for immunotherapies such as Immune Checkpoint Inhibitors, predict efficacy, and dynamically monitor their progress. This enables integrated, personalized treatment decisions encompassing diagnosis, medication, and efficacy evaluation, making it a crucial entry point technology within the precision medicine

The growth logic of immuno-oncology diagnostics is highly dependent on the expansion of tumor immunotherapy. With the continuous expansion of the indications for immunotherapies such as PD-1/PD-L1 in multiple cancer types, and the emergence of new therapies such as CAR-T and bispecific antibodies, the demand for precise patient screening and companion diagnostics is rapidly increasing. At the same time, the industry is upgrading from single biomarker detection to multi-omics integrated analysis, and the combination of liquid biopsy and AI algorithms is driving the trend of "non-invasive + dynamic" monitoring, significantly improving clinical value and frequency of use. At the regulatory level, the "drug + diagnostic" collaborative approval model is being strengthened, forming a deep bond between leading diagnostic companies and pharmaceutical companies, further raising industry barriers. It is expected that this field will continue to maintain medium-to-high-speed growth in the next 5-10 years, becoming one of the most core infrastructures in the precision medicine and cancer treatment system.

This report presents a comprehensive overview of the global Immuno-oncology Diagnosis market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Technology Path

• Immunohistochemistry
• Molecular Diagnostics
• High-Throughput Sequencing
• Liquid Biopsy
• Multi-omics Integrated Analysis

Segment by Detection Biomarkers

• Immune Checkpoint Biomarkers
• Tumor Mutation Burden
• Microsatellite Instability
• Tumor-Infiltrating Lymphocytes
• Immune-Related Gene Expression Profiling

Segment by Application

• Research
• Diagnostics

Segment by Application

• Immunodiagnostics for Solid Tumors
• Immunodiagnostics for Hematologic Malignancies
• Tumor Microenvironment (TME) Analysis

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Immuno-oncology Diagnosis market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Immunodiagnostics for Solid Tumors, Immunodiagnostics for Hematologic Malignancies, Tumor Microenvironment (TME) Analysis evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact